Showing 5971-5980 of 8784 results for "".
- Senate Passes Bill to Repeal SGRhttps://practicaldermatology.com/news/senate-passes-bill-to-repeal-sgr/2458967/This week saw the end of the sustainable growth rate (SGR), with the US Senate passing the Medicare Access and CHIP Reauthorization Act (H.R.2) in a 92-8 vote and President Obama signing it into law. The bill, which the Hous
- Foamix Pharmaceuticals Announces Upsizing and Pricing of Its Public Offeringhttps://practicaldermatology.com/news/foamix-pharmaceuticals-announces-upsizing-and-pricing-of-its-public-offering/2458968/Foamix Pharmaceuticals Ltd. (Nasdaq:FOMX), a specialty pharmaceutical company focused on developing topical foams to address unmet needs in dermatology, today announced the pricing of an upsized public offering of 6,451,612 ordinary shares at a price to the public of $9.30 per share. In addition,
- Cipher Pharmaceuticals Acquires Innocutishttps://practicaldermatology.com/news/cipher-pharmaceuticals-acquires-innocutis/2458969/Cipher Pharmaceuticals Inc. has acquired Innocutis Holdings LLC, a privately held specialty dermatology company, for US$45.5 million in cash. (All financial references are in U.S. dollars unless otherwise noted.) "This acquisition marks our commercial entry to the U.S. market an
- Dr. Reddy's and its Subsidiary Promius Pharma File Three NDAshttps://practicaldermatology.com/news/dr-reddys-and-its-subsidiary-promius-pharma-announce-filing-of-three-ndas/2458971/Dr. Reddy's Laboratories and its subsidiary, Promius Pharma, LLC filed three 505(b)(2) New Drug Applications (NDAs) with the FDA. The three NDAs - DFD-01, DFD-09, and DFN-11, are in support of Dr. Reddy’s Proprietary Products group, focused on developing and commercializing therapies in
- Provectus Biopharmaceuticals' Data on PV-10 to Be Presented at HemOnc Todayhttps://practicaldermatology.com/news/provectus-biopharmaceuticals-data-on-pv-10-to-be-presented-at-hemonc-today/2458972/Provectus Biopharmaceuticals, Inc., a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus"), announced that Dr. Sanjiv Agarwala will present data on PV-10, the Company's novel investigational drug for cancer, at the HemOnc Today Melanoma and Cutaneous
- Novan Secures $50 Million Private Financinghttps://practicaldermatology.com/news/novan-secures-50-million-private-financing/2458973/Novan Therapeutics, a clinical-stage biotechnology company focused on advancing innovation in dermatology via nitric oxide therapies, today announced that it has secured $50 million in an oversubscribed private financing. New investor Malin Corporation Plc. (MLC: ISE) functioned as the cornerston
- CareCredit Hosts Free Webinar on How to Host Successful Patient Eventshttps://practicaldermatology.com/news/carecredit-hosts-free-webinar-on-how-to-host-successful-patients-events/2458975/CareCredit will be sponsoring a free webinar to all aesthetic providers on how to host successful patient events. The webinar, How to Host Events That Bring Real Results: The Dos, Don’ts, and Definites, will be presented by Karen Zupko, President of Karen Zupko & Associate
- MDRejuvena Launches Novel Product Line Focused on Skin Healthhttps://practicaldermatology.com/news/mdrejuvena-launches-novel-product-line-focused-on-skin-health/2458978/MDRejuvena, Inc. launched its novel, proprietary product line at the American Academy of Dermatology Meeting in San Francisco. MDRejuvena's product line, designed to rejuvenate, enhance, and maintain skin health, incorporates Phytochromatic MDT Complex, a proprietary, patented, plant-derived
- Promius Pharma Launches Zenatane 30mg Dosehttps://practicaldermatology.com/news/promius-pharma-launches-zenatane-30mg-dose/2458977/Promius Pharma, LLC has announced that ZENATANE™(Isotretinoin Capsules USP) are now available in a 30mg dose. Zenatane, AB rated equivalent to Accutane 30mg, has been introduced in response to dermatologists who have continued to request this strength of the drug. <
- Dermira Presents Clinical Data for DRM01 Acne Programhttps://practicaldermatology.com/news/dermira-presents-clinical-data-for-drm01-acne-program/2458981/Dermira, Inc. presented clinical data from its DRM01 Phase 2a trial in patients with facial acne vulgaris. The primary endpoints in this trial, the changes from baseline in inflammatory and non-inflammatory lesion counts and an improvement in the Investigator's Global Assessment (IGA) of acne